{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-350445","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2026-08-14T12:00:16+00:00","discovered_at":"2026-08-14T12:05:01.402530+00:00","generated_at":"2026-08-14T12:06:26.698402+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PMV Pharma Q2 net loss $18.1M; completes PYNNACLE enrollment, NDA planned Q1 2027","bullets":["Net loss $18.1M for Q2 2026 vs $21.2M in Q2 2025; R&D expenses down to $14.7M from $18.4M.","Enrollment completed for primary analysis in Phase 2 monotherapy portion of PYNNACLE trial for platinum-resistant/refractory ovarian cancer.","NDA submission for rezatapopt accelerated approval planned Q1 2027.","Cash $79.4M as of June 30, 2026, down from $112.9M at Dec 31, 2025; runway through Q2 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-350445","json":"https://secwatch.observer/filing/0001193125-26-350445.json","markdown":"https://secwatch.observer/filing/0001193125-26-350445.md","text":"https://secwatch.observer/filing/0001193125-26-350445.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000119312526350445/0001193125-26-350445-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000119312526350445/pmvp-20260814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T12:06:26.698402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}